Belle Chiou

Partner and Head of Healthcare & Life Sciences
Baker McKenzie, Taipei (國際通商法律事務所)

Belle Chiou is the head of Healthcare and Life Sciences industry group of Baker McKenzie's Taipei office. Her practice encompasses mergers and acquisitions, corporate and commercial, and healthcare. She advises pharmaceutical, biotechnology, diagnostics, medical device and instrument companies, animal health, agro-pesticides, cosmetics, food and beverage companies, medical institutions and research institutes, and ICT industry on a broad range of commercial and regulatory matters. These include mergers and acquisitions, corporate development and licensing, partnerships and alliances, commercialization and product launches, regulatory compliance, pricing and reimbursement, data privacy and innovative technology products and services (digital health, precision medicine).
In addition to her legal practice, she has five years professional work experience as a researcher in a reputable medical center and has a strong background in the specialized fields of biochemistry and medical care.

Speech title & Synopsis

Development and Launch of AI/ML Products

Artificial intelligence (AI) algorithms play an increasingly important role in assisting healthcare providers with diagnosis and treatment recommendations, patient engagement and adherence, and administrative activities, among others. Software incorporating AI, and specifically the subset of AI known as machine learning (ML), has become an important part of an increasing number of medical devices. One of the greatest potential benefits of ML resides in its ability to create new and important insights from the vast amount of data generated during the delivery of health care every day.
In this section, Belle Chiou will discuss the key legal and regulatory issues, from the ideation stage to market, that innovators of AI/ML products should consider and share Baker McKenzie's experience with key takeaways.